Advisor Group’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Advisor Group’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$12K	Hold	200	–	–	﹤0.01%	4230
2019 Q3	$9K	Hold	200	–	–	﹤0.01%	4380
2019 Q2	$10K	Hold	200	–	–	﹤0.01%	4357
2019 Q1	$11K	Hold	200	–	–	﹤0.01%	4313
2018 Q4	$8K	Hold	200	–	–	﹤0.01%	4303
2018 Q3	$14K	Hold	200	–	–	﹤0.01%	4073
2018 Q2	$11K	Hold	200	–	–	﹤0.01%	4030
2018 Q1	$11K	Buy	200 +86	+75%	+$5.15K	﹤0.01%	4007
2017 Q4	$6K	Buy	114 +2	+2%	+$113	﹤0.01%	4326
2017 Q3	$7K	Buy	112 +2	+2%	+$114	﹤0.01%	4121
2017 Q2	$6K	Buy	+110	New	+$5.37K	﹤0.01%	4156
2016 Q4	–	Sell	-243	Closed	-$12K	–	4500
2016 Q3	$12K	Sell	243 -175	-42%	-$8.31K	﹤0.01%	3436
2016 Q2	$16K	Buy	+418	New	+$18K	﹤0.01%	3199

Other funds holding BIB

GWM

Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

SBIA

Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return

SkyOak Wealth Southfield, Michigan $612M AUM 23.73% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $7.59B AUM 23.38% 1-Year Est. Return

Advisor Group's BIB Position: Q4 2019 in Review

Advisor Group held its ProShares Ultra NASDAQ Biotechnology (BIB) position steady in Q4 2019 at 200 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #4230.

Advisor Group first reported a position in BIB in Q2 2016 and has held it in 13 quarters since. The position peaked at $16K in Q2 2016. 26 funds tracked by Wall St. Rank hold BIB as of Q4 2019.

Advisor Group held 200 shares of ProShares Ultra NASDAQ Biotechnology worth $12K as of Q4 2019.
Advisor Group left its ProShares Ultra NASDAQ Biotechnology share count unchanged in Q4 2019.
ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4230 holding.
Advisor Group first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2016 and has held it in 13 quarters since.
Advisor Group's ProShares Ultra NASDAQ Biotechnology position peaked at $16K in Q2 2016.
26 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.